SCYNEXIS, Inc. is a premier drug discovery and development company headquartered in Research Triangle Park, North Carolina. Its scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery of innovative medicines over a broad range of therapy areas.
Our track record in drug discovery is demonstrated by the eleven pre-clinical and clinical candidates that we have delivered to our partners in the last five years. In pursuit of our vision of bringing innovative drug pipeline solutions, SCYNEXIS is now building a unique and exciting drug discovery and development expertise in the area of cyclophilin inhibition. The Company’s first clinical candidate, SCY-635, is currently being studied in patients chronically infected with hepatitis C virus (HCV)—a disease for which there is a significant unmet need and which has the keen interest of the biopharmaceutical community. In addition, SCYNEXIS’s scientists are excited about the broader indications for cyclophilin inhibitors across a number of therapeutic indications. At the same time SCYNEXIS remains as committed as ever to delivering outstanding value to our fee for service and shared risk project customers.
In the discovery phase SCYNEXIS offers its services primarily in the form of integrated research teams consisting of medicinal chemists, biologists, computational chemists, biochemists, analytical chemists and bioanalytical scientists to work on a collaborative basis with our customers on projects from hit identification to candidate selection. SCYNEXIS project leaders of these multi-disciplinary teams are knowledgeable scientists with years of industry experience. They coordinate and communicate key activities and drive resources to achieve success. SCYNEXIS research teams use powerful, proprietary technologies such as its HEOS® SaaS data management and collaboration platform and its MEDCHEM-FACTORY® platform which efficiently integrates expertise in biology, biochemistry, ADMET-PK and medicinal chemistry with the best tools to deliver maximum results to our customers.
Development phase services such as process chemistry and cGMP synthesis are available on a fee for service project basis. SCYNEXIS has tailored its development teams to be especially effective in moving projects from discovery to the clinic. By linking good science with regulatory compliance, SCYNEXIS ensures projects are completed to meet both a client’s expectations and current GMP guidelines.